Alto Neuroscience Accelerates Development of ALTO-207 with New Financing and Positive Clinical Trial Results

Strategic Insights -

Alto Neuroscience has announced plans to expedite the development of ALTO-207, a novel treatment for treatment-resistant depression, following a successful meeting with the FDA. The company has secured $50 million in private placement financing, which will enable it to initiate a Phase 3 study by early 2027. Positive results from blinded pharmacokinetic analyses of ongoing Phase 2 studies for ALTO-100 and ALTO-101 have also strengthened the company's clinical trial execution efforts.

Key Takeaways:

  • Alto expects to initiate a Phase 2b, potentially pivotal, clinical trial of ALTO-207 in people with treatment-resistant depression by mid-2026.
  • The company now aims to initiate a Phase 3 clinical trial by early 2027 pending protocol alignment with the FDA and planned Phase 3 readiness work.
  • ALTO-207 is a fixed-dose combination of pramipexole and ondansetron, designed to enable rapid titration and higher dosing to mitigate dose-limiting adverse events.
  • The company has maintained cash guidance into 2028, now including additional development activities for ALTO-207.
  • ALTO-100, a treatment for bipolar depression, and ALTO-101, for cognitive impairment associated with schizophrenia, demonstrated positive results from blinded PK analysis, with 96% and 100% of samples qualifying as PK positive, respectively.
  • The updated guidance on topline data timing for ALTO-101 indicates that the company expects to report topline data from its Phase 2, proof-of-concept study in 1Q 2026.

Statistics:

  • The company has secured $50 million in private placement financing to support the accelerated development of ALTO-207.
  • Alto expects to initiate a Phase 3 clinical trial by early 2027.
  • The Phase 2, proof-of-concept study of ALTO-101 in CIAS is ongoing, with enrollment remaining steady.
  • 96% of samples for ALTO-100 and 100% of samples tested for ALTO-101 qualified as PK positive.

Sources:

  • Alto Neuroscience press release announcing the private placement financing and accelerated development plans for ALTO-207.
  • BusinessWire release announcing the company's plans to expedite the development of ALTO-207 following a successful FDA meeting.